IGF1 enhances platelet Akt phosphorylation and activity, eventually inducing thrombosis in murine model of type I diabetes.[44] Anti‐β2GPI antibodies could also activate platelet Akt pathway to promote thrombosis in APS patients.[45, 46] Targeting IGF1 pathway may provide a novel therapeutic approach for male patients with tAPS. The gene discussed is IGF1; the disease is autoimmune polyendocrinopathy.